{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:34:08Z","timestamp":1790847248549,"version":"4.1.0"},"reference-count":59,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["oncology"],"award-info":[{"award-number":["oncology"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0221635","type":"journal-article","created":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T13:59:33Z","timestamp":1570715973000},"page":"e0221635","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5563-3951","authenticated-orcid":true,"given":"Emilie A.","family":"Chapeau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeline","family":"Mandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0955-6470","authenticated-orcid":true,"given":"Jason","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Romanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Ebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violetta","family":"Powajbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Andraos-Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyan","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miltos","family":"Kininis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Zumstein-Mecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moriko","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy E.","family":"Hynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Tiedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Eshkind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Bockamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Kinzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Baffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Radimerski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,10,10]]},"reference":[{"issue":"9464","key":"pone.0221635.ref001","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"EJ Baxter","year":"2005","journal-title":"Lancet"},{"issue":"7037","key":"pone.0221635.ref002","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"C James","year":"2005","journal-title":"Nature"},{"issue":"17","key":"pone.0221635.ref003","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"R Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0221635.ref004","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"RL Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"10","key":"pone.0221635.ref005","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"AD Pardanani","year":"2006","journal-title":"Blood"},{"issue":"24","key":"pone.0221635.ref006","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1182\/blood-2008-12-194548","article-title":"Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms","volume":"113","author":"FH Grand","year":"2009","journal-title":"Blood"},{"issue":"36","key":"pone.0221635.ref007","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1200\/JCO.2009.23.7503","article-title":"Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies","volume":"27","author":"H Makishima","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7257","key":"pone.0221635.ref008","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature08240","article-title":"Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms","volume":"460","author":"M Sanada","year":"2009","journal-title":"Nature"},{"issue":"6","key":"pone.0221635.ref009","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood-2010-02-270108","article-title":"Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms","volume":"116","author":"ST Oh","year":"2010","journal-title":"Blood"},{"issue":"10","key":"pone.0221635.ref010","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/leu.2010.163","article-title":"LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations","volume":"24","author":"A Pardanani","year":"2010","journal-title":"Leukemia"},{"issue":"25","key":"pone.0221635.ref011","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"T Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"pone.0221635.ref012","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"J Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"22","key":"pone.0221635.ref013","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"R Rampal","year":"2014","journal-title":"Blood"},{"issue":"23","key":"pone.0221635.ref014","doi-asserted-by":"crossref","first-page":"11156","DOI":"10.1158\/0008-5472.CAN-06-2210","article-title":"Characterization of murine JAK2V617F-positive myeloproliferative disease","volume":"66","author":"TG Bumm","year":"2006","journal-title":"Cancer Res"},{"issue":"7","key":"pone.0221635.ref015","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Y Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"11","key":"pone.0221635.ref016","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","article-title":"Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model","volume":"107","author":"G Wernig","year":"2006","journal-title":"Blood"},{"issue":"17","key":"pone.0221635.ref017","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","article-title":"Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease","volume":"115","author":"H Akada","year":"2010","journal-title":"Blood"},{"issue":"5","key":"pone.0221635.ref018","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2009-12-257063","article-title":"Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice","volume":"116","author":"C Marty","year":"2010","journal-title":"Blood"},{"issue":"6","key":"pone.0221635.ref019","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells","volume":"17","author":"A Mullally","year":"2010","journal-title":"Cancer Cell"},{"issue":"8","key":"pone.0221635.ref020","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice","volume":"111","author":"R Tiedt","year":"2008","journal-title":"Blood"},{"issue":"10","key":"pone.0221635.ref021","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.1182\/blood-2007-05-091579","article-title":"Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice","volume":"111","author":"S Xing","year":"2008","journal-title":"Blood"},{"issue":"1","key":"pone.0221635.ref022","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.leu.2405043","article-title":"Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F","volume":"22","author":"K Shide","year":"2008","journal-title":"Leukemia"},{"issue":"11","key":"pone.0221635.ref023","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1084\/jem.20131371","article-title":"Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F","volume":"211","author":"P Lundberg","year":"2014","journal-title":"J Exp Med"},{"key":"pone.0221635.ref024","doi-asserted-by":"crossref","first-page":"82","DOI":"10.12688\/f1000research.13167.1","article-title":"JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders","volume":"7","author":"W Vainchenker","year":"2018","journal-title":"F1000Res"},{"issue":"9","key":"pone.0221635.ref025","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"C Harrison","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0221635.ref026","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"AM Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"pone.0221635.ref027","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"S Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0221635.ref028","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","article-title":"Myeloproliferative Neoplasms: A Contemporary Review.","volume":"1","author":"A Tefferi","year":"2015","journal-title":"JAMA Oncol"},{"issue":"7","key":"pone.0221635.ref029","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00277-017-2994-x","article-title":"Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study","volume":"96","author":"AM Vannucchi","year":"2017","journal-title":"Ann Hematol"},{"issue":"13","key":"pone.0221635.ref030","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/blood-2014-01-547760","article-title":"Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms","volume":"123","author":"N Bhagwat","year":"2014","journal-title":"Blood"},{"issue":"22","key":"pone.0221635.ref031","doi-asserted-by":"crossref","first-page":"6230","DOI":"10.1158\/1078-0432.CCR-13-0905","article-title":"JAK1\/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease","volume":"19","author":"E Evrot","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"7","key":"pone.0221635.ref032","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1182\/blood-2012-03-415646","article-title":"Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model","volume":"121","author":"L Kubovcakova","year":"2013","journal-title":"Blood"},{"issue":"4","key":"pone.0221635.ref033","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/leu.2011.261","article-title":"EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L","volume":"26","author":"G Wernig","year":"2012","journal-title":"Leukemia"},{"issue":"7","key":"pone.0221635.ref034","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.exphem.2015.03.006","article-title":"Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm","volume":"43","author":"AD Pomicter","year":"2015","journal-title":"Exp Hematol"},{"issue":"13","key":"pone.0221635.ref035","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","article-title":"The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis","volume":"126","author":"M Deininger","year":"2015","journal-title":"Blood"},{"issue":"21","key":"pone.0221635.ref036","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood-2015-01-624536","article-title":"JAK2V617F complete molecular remission in polycythemia vera\/essential thrombocythemia patients treated with ruxolitinib","volume":"125","author":"L Pieri","year":"2015","journal-title":"Blood"},{"issue":"5","key":"pone.0221635.ref037","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood-2018-02-785923","article-title":"How I treat myelofibrosis after failure of JAK inhibitors","volume":"132","author":"A Pardanani","year":"2018","journal-title":"Blood"},{"issue":"5","key":"pone.0221635.ref038","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1182\/blood-2005-12-012104","article-title":"Tetracycline-controlled transgenic targeting from the SCL locus directs conditional expression to erythrocytes, megakaryocytes, granulocytes, and c-kit-expressing lineage-negative hematopoietic cells","volume":"108","author":"E Bockamp","year":"2006","journal-title":"Blood"},{"issue":"5","key":"pone.0221635.ref039","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2006-02-002030","article-title":"JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis","volume":"108","author":"C Lacout","year":"2006","journal-title":"Blood"},{"key":"pone.0221635.ref040","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1371\/journal.pone.0000018","article-title":"Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F","volume":"1","author":"VM Zaleskas","year":"2006","journal-title":"PLoS One"},{"issue":"12","key":"pone.0221635.ref041","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1158\/1078-0432.CCR-10-2900","article-title":"Pathogenesis and consequences of uniparental disomy in cancer","volume":"17","author":"H Makishima","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"6","key":"pone.0221635.ref042","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S1525-0016(03)00104-7","article-title":"Lentiviral vectors with two independent internal promoters transfer high-level expression of multiple transgenes to human hematopoietic stem-progenitor cells","volume":"7","author":"X Yu","year":"2003","journal-title":"Mol Ther"},{"issue":"6","key":"pone.0221635.ref043","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.cell.2008.10.048","article-title":"Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair","volume":"135","author":"A Wilson","year":"2008","journal-title":"Cell"},{"issue":"3","key":"pone.0221635.ref044","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","article-title":"JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response","volume":"5","author":"M Kleppe","year":"2015","journal-title":"Cancer Discov"},{"issue":"7","key":"pone.0221635.ref045","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1158\/1535-7163.MCT-10-0053","article-title":"Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805","volume":"9","author":"F Baffert","year":"2010","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"pone.0221635.ref046","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/s41375-018-0207-9","article-title":"Dysregulated iron metabolism in polycythemia vera: etiology and consequences","volume":"32","author":"YZ Ginzburg","year":"2018","journal-title":"Leukemia"},{"issue":"16","key":"pone.0221635.ref047","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1073\/pnas.0601462103","article-title":"The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation","volume":"103","author":"CH Jamieson","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"pone.0221635.ref048","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.V100.1.238","article-title":"Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice","volume":"100","author":"SC Kogan","year":"2002","journal-title":"Blood"},{"issue":"7","key":"pone.0221635.ref049","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3324\/haematol.2009.014407","article-title":"Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders","volume":"95","author":"BL Stein","year":"2010","journal-title":"Haematologica"},{"issue":"7484","key":"pone.0221635.ref050","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nature12932","article-title":"Oestrogen increases haematopoietic stem-cell self-renewal in females and during pregnancy","volume":"505","author":"D Nakada","year":"2014","journal-title":"Nature"},{"issue":"6","key":"pone.0221635.ref051","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.stem.2014.11.002","article-title":"Estrogen signaling selectively induces apoptosis of hematopoietic progenitors and myeloid neoplasms without harming steady-state hematopoiesis","volume":"15","author":"A Sanchez-Aguilera","year":"2014","journal-title":"Cell Stem Cell"},{"issue":"9","key":"pone.0221635.ref052","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2009-12-259747","article-title":"JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia","volume":"116","author":"J Li","year":"2010","journal-title":"Blood"},{"issue":"19","key":"pone.0221635.ref053","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1182\/blood-2014-04-570572","article-title":"JAK2V617F+ myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2","volume":"124","author":"Y Kagoya","year":"2014","journal-title":"Blood"},{"issue":"7512","key":"pone.0221635.ref054","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nature13383","article-title":"Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms","volume":"512","author":"L Arranz","year":"2014","journal-title":"Nature"},{"issue":"1","key":"pone.0221635.ref055","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/asheducation-2014.1.287","article-title":"The evolving genomic landscape of myeloproliferative neoplasms","volume":"2014","author":"J Nangalia","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"pone.0221635.ref056","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/ajcp\/aqw222","article-title":"Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis","volume":"147","author":"J Song","year":"2017","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"pone.0221635.ref057","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/leu.2017.233","article-title":"The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms","volume":"32","author":"H Zhan","year":"2018","journal-title":"Leukemia"},{"issue":"7","key":"pone.0221635.ref058","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1002\/stem.1711","article-title":"Critical role of Jak2 in the maintenance and function of adult hematopoietic stem cells","volume":"32","author":"H Akada","year":"2014","journal-title":"Stem Cells"},{"issue":"13","key":"pone.0221635.ref059","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1182\/blood-2014-08-594572","article-title":"Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN","volume":"125","author":"J Grisouard","year":"2015","journal-title":"Blood"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0221635","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T20:15:27Z","timestamp":1588968927000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0221635"}},"subtitle":[],"editor":[{"given":"John W.","family":"Glod","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,10,10]]},"references-count":59,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,10,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0221635","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,10]]}}}